This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.0 | Special Copayment Reduction: V117 |
| B. Synonyms | McArdle disease, glycogen storage disease type V (GSD type V), Muscle phosphorylase deficiency, PYGM deficiency, muscle glycogenolysis disorder |
| C. Adult onset | Likelihood of first onset in adulthood high — symptom onset is mostly in childhood to adolescence, but in carriers of mild variants diagnosis is commonly delayed into adulthood. A substantial number of cases have been reported that were first diagnosed in adulthood with exercise intolerance, muscle cramps, or rhabdomyolysis. |
| 1. History | 1951, first description by McArdle → 1959, Schmid/Mahler confirm muscle phosphorylase deficiency → 1980s, PYGM research → 1989, cloning of the PYGM gene → standardization of the forearm ischemic test → shift to the non-ischemic exercise test. |
| 2. Causes | PYGM gene mutations → deficiency of skeletal muscle-specific glycogen phosphorylase (myophosphorylase) → inability to convert muscle glycogen → glucose-1-phosphate → energy supply blocked during exercise. Autosomal recessive. Liver and cardiac muscle phosphorylases are encoded by separate genes (PYGL, PYGB) and are therefore normal. |
| 3. Genetics | PYGM: 11q13.1, 20 exons. The p.Arg50Stop (c.148C>T, p.R50*) variant is the most common variant, found on at least one allele in about 60–70% of Western patients. Spain: p.W798* frequent. Japan/Korea: p.Arg94Trp and others. More than about 200 variants reported. |
| 4. General epidemiology | Prevalence about 1/100,000–1/167,000. The most common of the muscle GSDs, which account for about 1/3 or more of all GSDs. Relatively well studied in Spain, the UK, and North America. Equal frequency in males and females. |
| 5. Pathophysiology | Muscle glycogen phosphorylase deficiency → inability to break down muscle glycogen during exercise → insufficient ATP supply → muscle cramps and contractures. Mitochondrial fat oxidation and blood glucose can be used but are insufficient for early high-intensity exercise. With severe ischemia, rhabdomyolysis → myoglobinuria → acute renal failure. |
| 6. Symptoms | Exercise intolerance, muscle cramps and pain during exercise, muscle weakness after exercise. Characteristic "second wind" phenomenon (reactivation after initial exercise). Red urine (myoglobinuria) with strenuous exercise. Recurrent rhabdomyolysis → risk of acute renal failure. |
| 7. Signs | Physical examination at rest is often normal. Markedly elevated CK (elevated even at rest, further elevated after exercise). On the non-ischemic exercise test, no rise in blood lactate with a normal rise in ammonia (oxygen-debt pattern). EMG: intermittent myopathic changes or normal at rest. Muscle biopsy: PAS-positive glycogen vacuoles, negative phosphorylase histochemistry. |
| 8. Screening | Non-ischemic forearm exercise test in adults with exercise intolerance. CK measurement (persistent elevation at rest is a clue for suspicion). Confirmation of myoglobinuria in adolescents and adults with red urine. Measurement of muscle histochemical phosphorylase activity. PYGM gene analysis. |
| 9. Diagnosis | Non-ischemic forearm exercise test: no rise in venous lactate after exercise + normal rise in ammonia → suggests GSD V (pattern without lactate rise). Muscle biopsy: negative phosphorylase histochemistry (specific for PYGM). Confirmed by PYGM gene analysis. Measurement of CK, LDH, and myoglobin. |
| 10. Treatment | Glucose or fructose intake before exercise (improves aerobic exercise tolerance). Progressive aerobic exercise training (improves aerobic capacity + use of the second wind). Avoidance of high-intensity anaerobic exercise. Short-term creatine supplementation (some benefit reported). In acute rhabdomyolysis, adequate fluid administration and monitoring of renal function. Effect of vitamin B6 uncertain. No evidence-based gene therapy. |
| 11. Prognosis | Normal life expectancy. Recurrent rhabdomyolysis and acute renal failure are the main sources of morbidity. Fixed muscle weakness develops in some in older age. Quality of life can be maintained by adhering to exercise restrictions and appropriate aerobic training. Prevention of acute renal failure is key to long-term prognosis. |
| 12. Prevention | Avoidance of exercise that triggers rhabdomyolysis (high-intensity anaerobic, isometric contraction). Carbohydrate intake before exercise. Adequate fluid intake. Immediate fluid therapy for acute rhabdomyolysis. Carrying a medical alert card. Genetic counseling. |
| 13. References | Quinlivan R et al. Cochrane Database Syst Rev 2014 and 9 others |
The history of McArdle disease (GSD type V) began in 1951 when the British physician Brian McArdle described a 30-year-old male patient. Since childhood, this patient had developed muscle cramps and muscle pain with strenuous exercise and passed brown (red) urine after vigorous exercise. McArdle found that venous lactate did not rise during exercise in this patient (normally lactate rises with exercise) and inferred that glycolysis was not working properly in muscle, but at the time he could not identify the causative enzyme.
In 1959, Schmidt of Germany and Mahler of the United States independently demonstrated that glycogen phosphorylase activity was deficient in the muscle of patients with McArdle disease. The Coris classified it as type V glycogen storage disease. In 1966 the ischemic forearm exercise test (IFET) was developed, a method in which venous lactate and ammonia are measured after exercise with blood flow to the forearm occluded by a blood pressure cuff, and the characteristic pattern of no lactate rise in McArdle disease was used for diagnosis.
In the 1970s and 80s, the characteristic 'second wind' phenomenon of McArdle disease was explained physiologically. In early high-intensity exercise, ATP supply is insufficient because muscle glycogen cannot be broken down, but when exercise is briefly stopped or its intensity reduced, energy metabolism shifts to fatty acid oxidation and blood glucose use and exercise tolerance recovers. Understanding this phenomenon became the basis of exercise management for patients.
In 1989 the PYGM gene was cloned, and various pathogenic variants were subsequently identified. A particularly notable molecular epidemiological finding is that the p.Arg50Stop (c.148C>T) variant is found on at least one allele in about 60–70% of Western patients. In the 2000s, the safer non-ischemic forearm exercise test replaced the ischemic test and became standard. On the treatment side, aerobic training and carbohydrate intake before exercise were established as nonpharmacological strategies for improving exercise tolerance. Recently, mRNA therapeutics and AAV-based PYGM gene therapy have been studied in animal models.
McArdle disease (GSD type V) is an autosomal recessive genetic disease caused by deficiency of skeletal muscle-specific glycogen phosphorylase (myophosphorylase) due to pathogenic variants in the PYGM gene. Glycogen phosphorylase is the enzyme that phosphorolytically cleaves the α-1,4 bonds of glycogen with phosphate (Pi) to produce glucose-1-phosphate (G1P). The G1P produced is converted to G6P by phosphoglucomutase and used for ATP production through glycolysis.
There are three isoenzymes of glycogen phosphorylase in the human body. ① Muscle type (myophosphorylase, PYGM) — expressed specifically in skeletal muscle, encoded by the PYGM gene (11q13.1). ② Liver type (liver phosphorylase, PYGL) — expressed specifically in the liver, encoded by the PYGL gene (14q22.1). ③ Brain type (brain phosphorylase, PYGB) — expressed in brain and cardiac muscle, encoded by the PYGB gene (20p11.2). In McArdle disease only PYGM (muscle type) is deficient, and the liver type (PYGL) and brain/cardiac type (PYGB) are normal, so liver glycogen metabolism and cardiac muscle glycogen metabolism proceed normally. For this reason, McArdle disease has no hepatomegaly or hypoglycemia, and cardiomyopathy does not occur.
Because of myophosphorylase deficiency, glycogen in skeletal muscle cannot be used as an energy source. At rest this is not a problem, because the energy needs of muscle are met by fatty acid oxidation and blood glucose. However, during early high-intensity exercise or isometric contraction, instantaneous ATP demand rises sharply, and muscle glycogen breakdown is essential to meet it. In McArdle disease, ATP supply is blocked at this stage, causing muscle cramps, pain, and muscle stiffness. When sufficiently severe energy deficiency persists, muscle cell membrane damage (loss of membrane integrity) occurs, and rhabdomyolysis develops, in which muscle proteins (creatine kinase, myoglobin, LDH) are released into the bloodstream.
The PYGM gene is located on chromosome 11q13.1, spans about 18 kb in total, and consists of 20 exons. The translation product is myophosphorylase of 842 amino acids, with pyridoxal-5-phosphate (PLP, the active form of vitamin B6) functioning as a cofactor. PLP is essential for the activity and structural maintenance of the enzyme.
More than 200 pathogenic PYGM variants have been reported worldwide, including missense, nonsense, splicing, and small deletion/insertion variants. Most variants cause loss of myophosphorylase function.
Main variants: p.Arg50Stop (c.148C>T, former nomenclature: p.R49X) — a premature termination variant in exon 1 and the most common single variant, found on at least one allele in about 60–70% of Western (UK, North American, European) patients. In patients from Spain and of Spanish descent, the p.Trp798Stop (c.2392C>T) variant is relatively frequent. In Japanese patients, p.Arg94Trp (c.280C>T) has been reported as a founder variant, and similar East Asian-specific variants have been reported in Korean patients, but systematic studies of the Korean variant spectrum are limited.
Phenotype-genotype correlation: even with the same variant (including p.Arg50Stop homozygosity), there is considerable individual variation in clinical severity. This is because modifier genes, fitness level, physical activity patterns, body weight, and similar factors are important determinants of the clinical phenotype. In some missense variants, residual enzyme activity is partly maintained, and only milder exercise intolerance appears.
NGS-based whole-gene analysis of PYGM is standard for diagnostic confirmation and family counseling. Molecular diagnosis is also available for patients in Korea, and after the variant is identified, carrier testing of family members and prenatal diagnosis are performed.
The prevalence of McArdle disease (GSD type V) is estimated at about 1 in 100,000 births (1/167,000 in some studies), and it is the most common subtype of muscle GSD. Among all GSDs, it has the next highest frequency after GSD I and III. There is no difference in frequency by sex, but a tendency toward earlier and more severe clinical presentation in males has been reported, explained by men on average engaging in more high-intensity physical activity than women.
Research on McArdle disease is very active in Spain, where a national patient cohort has been established, and the p.Trp798Stop founder variant is found at high frequency in patients of Spanish descent. In the UK and North America, the p.Arg50Stop variant has also been identified at high frequency. A Japanese cohort study reported a high frequency of the p.Arg94Trp variant and a clinical course different from that in Western patients (difference in the frequency of fixed muscle weakness).
Epidemiological data on McArdle disease in Korea are limited, but it is not uncommonly diagnosed in patients presenting with exercise intolerance and recurrent rhabdomyolysis. In particular, when rhabdomyolysis is found as the cause of acute renal failure and there is a history of recurrence, McArdle disease should be included in the differential diagnosis. In Korea, few patients are registered for Special Copayment Reduction (V117), but diagnosis is possible through the non-ischemic forearm exercise test and PYGM gene analysis.
Life expectancy in McArdle disease is often normal, but from an epidemiological standpoint, education on exercise management to prevent acute renal failure due to recurrent rhabdomyolysis is an important preventive strategy.
The core pathophysiology of McArdle disease is blockade of muscle energy (ATP) supply during exercise due to myophosphorylase deficiency in skeletal muscle. In normal skeletal muscle, ATP during exercise is supplied mainly through three pathways. ① Phosphocreatine (PCr) breakdown — very fast but depleted within a few seconds to 15 seconds. ② Muscle glycogen breakdown (glycolysis) — rapid ATP production even without oxygen during early high-intensity exercise. ③ Oxidative phosphorylation of fatty acids and glucose — slow but sustained ATP supply.
In McArdle disease, pathway ② is blocked. During early high-intensity exercise or isometric contraction, after PCr is rapidly depleted, the shift to glycolysis does not occur and ATP supply becomes insufficient. As a result, muscle contraction does not proceed properly, and muscle fibers enter a state of forced contraction (contracture), with severe pain. If this state persists, muscle cell membrane damage occurs, and rhabdomyolysis develops, in which intracellular proteins (CK, myoglobin, LDH, aldolase) leak into the bloodstream.
Second wind phenomenon: when intensity is briefly reduced or exercise stopped after early high-intensity exercise (about 8–10 minutes), energy metabolism shifts to fatty acid oxidation and blood glucose use. In this process, exercise-induced sympathetic activation promotes glucose release from the liver (since PYGL is normal), and lipolysis in adipose tissue increases, raising free fatty acids available to muscle. Once this shift is complete, muscle can meet its energy needs with fatty acids and glucose and exercise tolerance recovers; this is the second wind phenomenon. It is highly specific to McArdle disease and is a clue to clinical diagnosis.
Rhabdomyolysis and acute renal failure: after strenuous exercise, large amounts of myoglobin are released into the bloodstream and blood myoglobin rises sharply. Myoglobin precipitates in the renal tubules, obstructing them and exerting direct toxicity, causing acute tubular necrosis (ATN). The resulting acute renal failure is the most serious acute complication of McArdle disease. Repeated episodes of rhabdomyolysis can progressively damage renal function.
The main clinical symptom of McArdle disease (GSD type V) is exercise intolerance. Most patients experience from childhood that, compared with peers, they cannot sustain vigorous exercise for long and that muscle cramps and pain develop with exercise. However, when symptoms are mild, it is not uncommon for diagnosis not to be made until adulthood.
Exercise intolerance and muscle cramps: muscle cramps and pain develop with brief high-intensity exercise (running, climbing stairs, lifting heavy objects) or isometric contraction (arm wrestling, gripping objects by hand). Initially recovery occurs within minutes when exercise stops, but in severe cases symptoms may last for hours. The typical pattern is that severe muscle cramps develop about 8–10 minutes after starting exercise, and after a brief stop or reduction in intensity, recovery through the 'second wind' phenomenon allows exercise to resume. Most patients experience this second wind but do not recognize it as a disease until they are diagnosed.
Myoglobinuria and rhabdomyolysis: when muscle damage is severe after excessive exercise, the urine turns reddish-brown (cola color) because myoglobin is excreted in the urine. When this symptom occurs repeatedly, McArdle disease should be strongly suspected. In episodes with myoglobinuria, there is a risk of acute renal failure, and immediate fluid therapy is needed.
Muscle weakness after exercise: after a severe exercise episode, muscle weakness and fatigue may persist for hours to days. During this period even daily activities may feel difficult.
Fixed muscle weakness: in some patients (especially older patients), when recurrent rhabdomyolysis and chronic muscle damage accumulate, permanent proximal muscle weakness develops. This is rare in young patients and tends to develop after middle age.
Physical examination findings in patients with McArdle disease at rest are mostly normal or nonspecific. Characteristic findings are observed on examination during or immediately after exercise.
Findings at rest: most patients have a normal build and muscle appearance. In patients with progressive fixed muscle weakness, proximal muscle weakness and muscle atrophy may be observed. Deep tendon reflexes are normal. There is no hepatomegaly, splenomegaly, or cardiomegaly.
Laboratory findings: serum CK is persistently elevated even at rest (3–10 times normal, sometimes higher) and rises even more markedly immediately after exercise. LDH and myoglobin are also elevated. Serum uric acid is generally normal but may rise with recurrent rhabdomyolysis. Liver and kidney function, blood glucose, and electrolytes are generally normal.
Non-ischemic forearm exercise test findings: after repeated maximal voluntary contractions (about 1 minute) using the forearm flexors, venous blood is drawn. Normally, both lactate (2–3 times or more) and ammonia (3–5 times or more) rise after exercise. In McArdle disease, lactate does not rise or rises only minimally, but ammonia rises normally (because the muscle purine nucleotide cycle operates normally). This pattern of 'no lactate rise + normal ammonia rise' is the characteristic diagnostic finding of McArdle disease. Conversely, if neither lactate nor ammonia rises, the patient did not make a maximal exercise effort, and the test must be repeated.
Muscle biopsy findings: PAS-positive glycogen vacuoles between muscle fibers (vacuolar glycogen accumulation) and subsarcolemmal glycogen accumulation are characteristic. On phosphorylase histochemical staining, negative enzyme activity in muscle fibers (smooth muscle cells of vessel walls contain PYGB and stain positive, serving as an internal control) is highly specific for McArdle disease.
There is no universal newborn screening for McArdle disease. Early screening based on clinical symptoms, the non-ischemic forearm exercise test, CK measurement, and genetic analysis are the practical approach.
Clinical screening clues: ① exercise intolerance (muscle cramps and pain, especially with high-intensity or isometric exercise). ② Red urine after exercise (myoglobinuria). ③ Recurrent rhabdomyolysis (after exclusion of other causes). ④ Persistently elevated CK (even at rest). ⑤ The second wind phenomenon. Among these, the combination of myoglobinuria and second wind is highly specific for McArdle disease.
Non-ischemic forearm exercise test (NIFET): a safe screening test that replaces the ischemic test (using a blood pressure cuff). Venous lactate and ammonia are measured at 0, 1, 3, 5 and 10 minutes while the forearm flexors are contracted repeatedly at maximal effort for 1 minute. In McArdle disease, a pattern appears in which lactate does not rise even after exercise (less than 2 times baseline).
CK measurement: if a persistent CK elevation at rest (3–10 times normal or more) is confirmed, causes such as inflammatory muscle disease, endocrine disease, other GSDs and adverse drug effects are excluded, and then hereditary myopathies including McArdle disease are differentiated. Family history (autosomal recessive), a history of exercise intolerance from an early age, and episodes of red urine are screening clues for McArdle disease.
Family history-based testing: PYGM gene testing in siblings of patients with McArdle disease confirms whether they are affected at an early stage, and by providing education in advance (avoidance of high-intensity exercise, fluid intake), the first episode of rhabdomyolysis can be prevented.
McArdle disease is confirmed by a combination of the non-ischemic forearm exercise test, muscle biopsy (phosphorylase histochemistry) and PYGM gene analysis. Currently, gene analysis is the least invasive and most definitive method of confirmation.
Non-ischemic forearm exercise test (NIFET): as described above, a pattern of no lactate rise + normal ammonia rise after exercise strongly suggests McArdle disease. Because this pattern can also occur in other muscle GSDs (GSD VII, phosphoglycerate kinase deficiency, etc.), genetic confirmation is required. However, if the patient does not exert maximal exercise effort, a false negative (no lactate rise, but due to insufficient exercise) may occur.
PYGM gene analysis: NGS-based analysis of all 20 PYGM exons + CNV analysis confirms the diagnosis when biallelic pathogenic variants are identified. If only a single variant is identified, CNV analysis (large deletions) is added. Because the p.Arg50Stop variant is common on one allele in Western patients, analysis of the second allele is performed after this variant is identified.
Muscle biopsy: the traditional confirmatory method, but it is increasingly being replaced by gene analysis. Light microscopy: PAS-positive vacuolated fibers, subsarcolemmal glycogen accumulation. Phosphorylase histochemistry: loss of activity in muscle fibers (vascular smooth muscle is positive due to PYGB — internal control). Electron microscopy: overload of glycogen particles. When confirmation by gene analysis is difficult or no variant is found, muscle biopsy provides additional clues.
Evaluation of acute rhabdomyolysis: during an acute episode, elevated CK (tens of thousands to hundreds of thousands IU/L), myoglobin, LDH and aldolase, and positive urine myoglobin. Renal function (creatinine, BUN, urinalysis) is used to assess for acute tubular injury. Electrolyte abnormalities (hypercalcemia, hypocalcemia, hyperkalemia) are risk factors for cardiac arrhythmia and are therefore monitored.
There is currently no specific enzyme replacement therapy or approved drug treatment for McArdle disease; the core of treatment is exercise management and prevention of acute complications (rhabdomyolysis, acute renal failure).
Pre-exercise carbohydrate intake: ingestion of glucose or sucrose 30–60 minutes before exercise (about 75 g glucose equivalent) raises blood glucose, supplies an alternative energy source to muscle, and improves exercise tolerance. In actual clinical practice, patients are taught to take a glucose drink (sports drink, glucose gel) before exercise. This helps reduce exercise-induced CK elevation and the occurrence of myoglobinuria.
Progressive aerobic exercise training: in McArdle disease, regular moderate-intensity aerobic exercise training (walking, swimming, cycling) improves overall aerobic capacity (VO2max), brings forward the onset of the second wind, and improves activities of daily living. A study by Munguía-Izquierdo et al. (2012) confirmed that regular aerobic training significantly improves exercise capacity and quality of life in patients with McArdle disease. However, because excessively high intensity at the start can actually trigger rhabdomyolysis, progressive training matched to individual exercise tolerance is important.
Using the second wind: patients are educated about the second wind phenomenon and taught to induce the shift to fatty acid oxidation metabolism with initial exercise (walking, warm-up) and then increase to the target exercise intensity. For example, starting the main exercise after 5–10 minutes of low-intensity pedaling before cycling reduces the risk of rhabdomyolysis.
Creatine supplementation: studied on the theoretical basis that it increases intramuscular PCr stores and enables additional ATP supply during initial exercise, but clinical results are inconsistent. Low doses (3 g/day or less) are beneficial in some patients, while high doses require caution because CK elevation and a risk of rhabdomyolysis have been reported.
Treatment of acute rhabdomyolysis: immediate and adequate intravenous fluid administration (normal saline, target urine output 200–300 mL/hr) is key. Urine alkalinization (adding sodium bicarbonate) may reduce myoglobin toxicity. Correction of electrolyte abnormalities (hyperkalemia, hypocalcemia, hypercalcemia). Hemodialysis is required when renal function is severely reduced. After admission, CK and renal function are monitored until CK shows a downward trend.
Life expectancy in McArdle disease (GSD type V) is mostly normal. However, acute renal failure and chronic decline in renal function due to recurrent rhabdomyolysis, and progressive fixed muscle weakness in some patients, are the main causes of morbidity. Quality of life may be reduced by exercise limitation, but it can be substantially maintained with appropriate education and exercise management.
Acute renal failure: during acute rhabdomyolysis from a severe exercise episode, acute tubular necrosis caused by myoglobin can lead to acute renal failure requiring dialysis. In most cases renal function recovers within a few weeks, but recurrence carries a risk of chronic decline in renal function. The first episode of rhabdomyolysis often leads to the diagnosis.
Fixed muscle weakness: when recurrent rhabdomyolysis and chronic muscle damage accumulate, permanent fixed weakness of proximal muscle strength develops. It mainly occurs after the 40s–50s, and walking aids may become necessary. In a Spanish cohort study, about 25–50% of patients experienced some degree of permanent weakness at an older age.
Quality of life: limited exercise capacity affects hobbies, career choice and social participation. High-intensity physical labor and competitive sports should be avoided, but health can be maintained with appropriate aerobic exercise. Participation in patient support groups and psychological support contribute to quality of life.
The key prevention strategy for McArdle disease is to avoid exercise that triggers rhabdomyolysis and to increase exercise tolerance through pre-exercise carbohydrate intake and appropriate aerobic training.
Exercise avoidance guidance: patients are educated to avoid high-intensity anaerobic exercise (sprinting, repeated heavy weight lifting, arm wrestling, strenuous stair climbing) and tasks involving isometric contraction (gripping tightly, carrying heavy objects). A gradual increase in intensity is safer than exercise in which intensity rises suddenly. Hot weather and dehydration increase the risk of rhabdomyolysis, so adequate fluid intake and maintenance of body temperature are important.
Emergency preparedness: patients are educated to stop exercise immediately if red urine occurs, drink plenty of fluids (water), and visit the emergency department if necessary. All patients should carry a Medical Alert ID so that they can inform medical staff of the disease during emergency care. Before surgery, the anesthesia and surgical teams must be informed of McArdle disease, and care is taken to avoid positions that load the muscles (prolonged unilateral positioning) and overheating.
Genetic counseling: carrier testing within the family and prenatal diagnosis are possible. It is recommended to confirm whether siblings are affected through early genetic testing and to start education on rhabdomyolysis prevention early.